 |
PDBsum entry 3pfq
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.11.13
- protein kinase C.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
Bound ligand (Het Group name = )
matches with 81.25% similarity
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
Bound ligand (Het Group name = )
matches with 81.25% similarity
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
Cell
144:55-66
(2011)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure and allosteric activation of protein kinase C βII.
|
|
T.A.Leonard,
B.Różycki,
L.F.Saidi,
G.Hummer,
J.H.Hurley.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Protein kinase C (PKC) isozymes are the paradigmatic effectors of lipid
signaling. PKCs translocate to cell membranes and are allosterically activated
upon binding of the lipid diacylglycerol to their C1A and C1B domains. The
crystal structure of full-length protein kinase C βII was determined at 4.0 Å,
revealing the conformation of an unexpected intermediate in the activation
pathway. Here, the kinase active site is accessible to substrate, yet the
conformation of the active site corresponds to a low-activity state because the
ATP-binding side chain of Phe629 of the conserved NFD motif is displaced. The
C1B domain clamps the NFD helix in a low-activity conformation, which is
reversed upon membrane binding. A low-resolution solution structure of the
closed conformation of PKCβII was derived from small-angle X-ray scattering.
Together, these results show how PKCβII is allosterically regulated in two
steps, with the second step defining a novel protein kinase regulatory mechanism.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |